OSR Holdings, Inc. (NASDAQ:OSRH) Sees Significant Decline in Short Interest

OSR Holdings, Inc. (NASDAQ:OSRH) saw a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 454,339 shares, a drop of 58.5% from the January 15th total of 1,094,583 shares. Based on an average daily volume of 1,211,313 shares, the days-to-cover ratio is presently 0.4 days. Currently, 4.5% of the shares of the company are sold short. Currently, 4.5% of the shares of the company are sold short. Based on an average daily volume of 1,211,313 shares, the days-to-cover ratio is presently 0.4 days.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR as of its most recent filing with the Securities & Exchange Commission. 55.30% of the stock is owned by hedge funds and other institutional investors.

OSR Price Performance

OSRH stock traded up $0.03 during midday trading on Friday, hitting $0.50. 279,223 shares of the stock traded hands, compared to its average volume of 2,315,974. The stock’s fifty day simple moving average is $0.63 and its 200-day simple moving average is $0.64. The firm has a market cap of $12.72 million, a P/E ratio of -0.44 and a beta of 1.41. OSR has a 1-year low of $0.45 and a 1-year high of $10.00.

OSR (NASDAQ:OSRH) last announced its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $0.63 million during the quarter.

Analysts Set New Price Targets

A number of equities research analysts have commented on OSRH shares. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a report on Monday, December 29th. Wall Street Zen raised shares of OSR to a “sell” rating in a research report on Saturday, October 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, OSR currently has a consensus rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.